CClinicalTrials.gg
RecruitingNCT05712577MARFANPSYUpdated Jan 12, 2024

Psychological Support in Adult Patients With Marfan Syndrome

An observational study in Rare Diseases, Marfan Syndrome and Psychology, Social, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by IRCCS Policlinico S. Donato · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
125
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to identify key factors leading to psychotherapy or psychological support in adult subjects with Marfan syndrome (MSF). the main questions it aims to answer are:

  • Understand and define which internal variables of the individual drive this request for psychological support;
  • To learn about verify the impact that the clinical manifestations of MSF have on psychosocial aspects, self-esteem, subjective perception of the disease and coping mechanisms.
Read the detailed description

Patients following psychological interview during follow-up visits will be enrolled in the study.

The following self-report questionnaires will be used in understanding the impact the syndrome has on mental health and quality of life:

  • Rosenberg Self- Esteem: 10 item Likert scale for assessing self-esteem;
  • SF 36: 36 item scale assessing eight domains: physical functioning physical role limitations; bodily pain; general health perceptions; energy/vitality; social functioning; emotional role limitations and mental health;
  • Cope NVI: to test measures coping behaviors as potential responses to stressors like social support, avoidance strategies, positive attitude, problem orientation and transcendent orientation;
  • OQ45.2: measure of general psychological distress.
02

Conditions studied

  • Rare Diseases
  • Marfan Syndrome
  • Psychology, Social

Keywords

  • Marfan syndrome
  • Psychological support
  • Self-report
03

In context

Marfan Syndrome

71 studies on the registry are indexed under Marfan Syndrome; 16 are open to participants now.

This study's planned enrollment of 125 is close to the median of 119 across 40 observational studies indexed under Marfan Syndrome.

Browse Marfan Syndrome studies →

Lead sponsor

IRCCS Policlinico S. Donato is the lead sponsor of 101 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with MFS who have requested psychological support/psychotherapy and patients who have never requested psychological support/psychotherapy.

Inclusion criteria

  • Subjects affected by Marfan syndrome;
  • Subjects currently in follow-up at Cardiovascular Genetic Centre, IRCCS Policlinico San Donato;
  • Signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Subjects with cognitive deficits
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
125 participants (estimated)
Patient registry
No

Groups and cohorts

  • MFS_PT+

    MFS patients who followed psychological support/psychotherapy

    Other: Questionnaire

  • MFS_PT-

    MFS patients who never followed psychological support/psychotherapy

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    Rosenberg Self- Esteem scale

  • OtherQuestionnaire

    Short Form 36 scale

  • OtherQuestionnaire

    Coping orientation to the problems experienced - New Version in Italian

  • OtherQuestionnaire

    Outcome Questionnaire - version 42.5

06

What researchers measure

Primary outcomes

  1. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: - COPE NVI: scoring between 60 and 240; higher score means better outcome

    Time frame: 8 Months

  2. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: - Short Form-36: scoring between 0 and 100; higher score means better outcome

    Time frame: 8 Months

  3. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: - Rosenberg Self- Esteem scale: scoring between 0 and 30; higher score means better outcome

    Time frame: 8 Months

  4. Questionnaire performance

    Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables. Questionnaire scoring: - Outcome questionnaire 42.5: socring between 0 and 180; clinical cut-off value is 64, higher score means worse outcome

    Time frame: 8 Months

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05712577
Lead sponsor
IRCCS Policlinico S. Donato
Responsible party
Alessandro Pini (Principal Investigator, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Feb 3, 2023
Start date
Jan 9, 2023
Primary completion
Oct 9, 2024 (estimated)
Completion
Oct 9, 2024 (estimated)
Last update
Jan 12, 2024

Study contacts

Alessandro Pini, MD
Contact
alessandro.pini@grupposandonato.it
+390252774705
Alessandro Pini, MD
principal investigator · Cardiovascular-Gentic Centre, IRCCS Policlinico San Donato

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion